1. 1406 Childhood Orbital Rhabdomyosarcoma. Report from Children's Cancer Hospital-57357-Egypt. Issue 3 (September 2015) Authors: Elnadi, E.; Hafiz, H.; Elzomor, H.; Labib, R.; Alfaar, A.; Zaghloul, M.; Taha, H.; Younes, A.; Elwakel, M. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (June 2017) Authors: Sauter, C.S.; Matasar, M.J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M.L.; Portlock, C.S.; Straus, D.J.; Zelenetz, A.D.; McCall, S.S.; Miller, S.T.; Courtien, A.I.; Younes, A.; Moskowitz, C.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA. (June 2017) Authors: Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P.M.; Batlevi, C.L.; Chen, R.; Constine, L.S.; Courtien, A.I.; Dandapani, S.V.; Drullinsky, P.; Friedberg, J.W.; Hamlin, P.A.; Hoppe, R.T.; Matasar, M.J.; McArthur, G.N.; Miller, S.T.; Moskowitz, A.J.; Noy, A.; Schoder, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A review on shape memory metallic alloys and their critical stress for twinning. (February 2019) Authors: Nnamchi, P.; Younes, A.; González, S. Journal: Intermetallics Issue: Volume 105(2019:Feb.) Page Start: 61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. An advanced numerical model for energy conversion and crack growth predictions in Solid Oxide Fuel Cell units. (14th December 2015) Authors: Shao, Q.; Fernández-González, R.; Ruiz-Morales, J.C.; Bouhala, L.; Fiorelli, D.; Younes, A.; Núñez, P.; Belouettar, S.; Makradi, A. Journal: International journal of hydrogen energy Issue: Volume 40:Number 46(2015) Page Start: 16509 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE. (June 2017) Authors: Moskowitz, A.J.; Schöder, H.; Gavane, S.; Thoren, K.L.; Fleisher, M.; Yahalom, J.; McCall, S.J.; Fox, S.Y.; Gerecitano, J.; Grewal, R.; Hamlin, P.A.; Horwitz, S.; Kumar, A.; Matasar, M.; Ni, A.; Noy, A.; Palomba, M.L.; Perales, M.; Portlock, C.S.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA. (12th June 2019) Authors: Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D.J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; Hamlin, P.; Zelenetz, A.; Matasar, M.; von Keudell, G.; Sermer, D.; Yahalom, J.; Dogan, A.; Seshan, V.; Younes, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. CLINICAL SIGNIFICANCE AND OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) HARBORING EXTRA COPIES [EC] AND/OR TRANSLOCATIONS [TL] OF MYC, BCL2, AND BCL6. (12th June 2019) Authors: Sermer, D.; Bobillo, S.; Seshan, V.; Dogan, A.; Younes, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 349 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B‐CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL. (12th June 2019) Authors: Balasubramanian, S.; Wang, S.; Major, C.; Hodkinson, B.; Schaffer, M.; Sehn, L.H.; Johnson, P.; Zinzani, P.L.; Carey, J.; Liu, G.; Loefgren, C.; Shreeve, M.; Sun, S.; Zhuang, S.; Vermeulen, J.; Staudt, L.M.; Younes, A.; Wilson, W. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA. (June 2017) Authors: Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P.; Horwitz, S.; Kumar, A.; Matasar, M.; Moskowitz, A.; Moskowitz, C.; Noy, A.; Palomba, M.; Portlock, C.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗